July 28, 2015

New report on investment in R&D for HIV prevention highlights 2014 global funding trends

Marissa Chmiola
Communications Officer

In this guest post, the HIV Vaccines & Microbicides Resource Tracking Working Group—comprised of AVAC as secretariat, the International AIDS Vaccine Initiative , and UNAIDS—discusses its new report examining investment in research and development (R&D) for HIV prevention options.


Investment in R&D for HIV prevention fell slightly, from US$1.26 billion to $1.25 billion, between 2013 and 2014 and has largely been stagnant for nearly a decade, according to a new report from the HIV Vaccines & Microbicides Resource Tracking Working Group which looks at year-over-year spending on HIV prevention R&D and trends spanning the last 15 years.

The report, HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities to Fund Innovation in an Evolving Global Health and Development Landscape, provides detailed information on funding for R&D on HIV prevention options—including preventive HIV/AIDS vaccines, microbicides, pre-exposure prophylaxis (PrEP), the use of AIDS treatment by people living with HIV to reduce transmission, the use of AIDS treatment to prevent infections in infants born to women living with HIV, voluntary medical male circumcision, and female condoms. In addition to funding information for R&D for HIV prevention options, the report also provides an update on investment in HIV cures, therapeutic vaccines, herpes (HSV-2) vaccines, and multipurpose prevention technology research.

Despite the slight decline in funding, HIV prevention R&D is still delivering important advances. The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention held in Vancouver from July 20-22, showcased results for a range of groundbreaking research that has been supported over the past several years, including the Strategic Timing of Antiretroviral Treatment (START) trial, the HPTN 052 antiretroviral (ARV) treatment as prevention trial, and several groundbreaking oral PrEP trials. Results from studies of a vaginal ring containing the ARV dapivirine are expected in the next 12 months. Several different HIV/AIDS vaccine candidates, neutralizing antibodies, and long-acting injectable ARVs are currently in studies that could lead to multiple efficacy trials starting over the next two years. Robust ongoing investment will be critical to advancing these promising products through the R&D process.

Through their research and analysis, the Working Group identified four key findings about the state of funding for HIV prevention R&D which are highlighted in the report:

For further analysis of HIV prevention funding trends, visit the Working Group's website at to download HIV Prevention Research & Development Funding Trends 2000–2014: Investing in innovation in an evolving global health and development landscape and to view additional Working Group reports, as well as graphics and PowerPoint slides.

Posted in: